European Society of Cardiology
European Society of Cardiology
September 18, 2019
7 min watch

VIDEO: Top takeaways from ESC Congress with Deepak L. Bhatt, MD, MPH

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, highlights “practice-changing” research presented at the 2019 European Society of Cardiology Congress.

Bhatt provides his take on results of top trials including THEMIS and THEMIS-PCI, which evaluated ticagrelor (Brilinta, AstraZeneca) compared with placebo in stable patients with diabetes; DAPA-HF, an investigation of SGLT2 inhibition with dapagliflozin (Farxiga, AstraZeneca) in patients with HF, with and without diabetes; PARAGON-HF, a comparison of sacubitril/valsartan (Entresto, Novartis) compared with valsartan alone for HF with preserved ejection fraction; and COMPLETE, an evaluation of complete revascularization compared with culprit lesion-only PCI in patients with STEMI and multivessel CAD.

Watch the video for more.